However, looking at the clinical perspective, since approximately 70% of SCN patients with AML harbor additional mutations in the RUNX1 gene, patients with SCN who are positive for CSF3R and/or RUNX1 mutation should be also transplanted to minimize the risk of MDS/AML occurrence. The gene discussed is RUNX1; the disease is severe congenital neutropenia.